Trial · NCT07159373
Better Options for Lymphatic Filariasis Treatment
NCT07159373, Phase 3, Recruiting, Medicines Development for Global Health
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Better Options for Lymphatic Filariasis Treatment. Trials, record NCT07159373. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07159373
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Better Options for Lymphatic Filariasis Treatment
- NCT number
- NCT07159373
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 5,100 participants, estimated
- Lead sponsor
- Medicines Development for Global Health
- Conditions
- Lymphatic Filariasis, Scabies, Strongyloidiasis
- Interventions
- MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole
- First posted
- 2025-09-08
- Last updated
- 2026-10-07
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of microfilariae (Mf)-positive participants at Baseline who are Mf-negative at Month 12 following treatment with MoxDA or IDA | 12 months post-treatment | Lymphatic filariasis (LF) Mf measured by ultrafiltration |
| Primary | Incidence and severity of adverse events | 7 days, 12 months and 24 months post-treatment | Frequency, type, and severity of adverse events reported by treatment group |
| Secondary | Proportion of Mf-positive participants at Baseline who are Mf-negative at Month 24 following treatment with MoxDA or IDA | 24 months post-treatment | LF Mf measured using ultrafiltration |
| Secondary | Mean Mf density and mean change from Baseline at Months 12 and 24 following treatment with MoxDA or IDA in participants who are Mf-positive at Baseline | 12 and 24 months post-treatment | LF Mf measured using ultrafiltration |
| Secondary | Proportion of participants who are circulating filarial antigen (CFA)-positive at baseline who become CFA-negative at Months 12 and/or 24 following treatment with MoxDA or IDA | 12 and 24 months post-treatment | CFA measured using rapid lateral flow assay |
| Secondary | Change in community prevalence of LF, as measured by Mf, at Months 12 and 24 following annual MDA with MoxDA or IDA, in addition to directed treatment of individuals who are Mf positive at 3-monthly assessments between Months 12 and 24 | 12 and 24 months post-treatment | LF Mf measured using ultrafiltration |
| Secondary | Change in community prevalence of LF, as measured by CFA, at Months 12 and 24 following annual MDA with MoxDA or IDA, in addition to directed treatment of individuals who are Mf positive at 3-monthl | 12 and 24 months post-treatment | CFA measured using rapid lateral flow assay |
| Secondary | Proportion of participants with presence of Mf between Month 12 and Month 24 among those who were Mf positive at Month 12 following treatment with MoxDA or IDA | 12 to 24 months post-treatment | LF Mf measured using ultrafiltration |
| Secondary | Time to first detection of Mf in participants with presence of Mf between Month 12 and Month 24 among those who were Mf positive at Month 12 following treatment with MoxDA or IDA | 12 to 24 months post-treatment | Lf Mf measured using ultrafiltration |
| Secondary | Community acceptability of MDA with MoxDA or IDA assessed by surveys, focus group discussions, and/or key informant interviews before Baseline and approximately 2 months following MDA at Baseline and Month 12 | Pre- and post-treatment at Baseline and post-treatment at Month 12 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07159373
GET https://conductscience.org/api/trials/v1/NCT07159373/registered